Warning: The NCBI web site requires JavaScript to function. more...
Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.
Steinfeld SD, Tant L, Burmester GR, Teoh NK, Wegener WA, Goldenberg DM, Pradier O.
Arthritis Res Ther. 2006;8(4):R129.
Related citations
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.
Dörner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR.
Arthritis Res Ther. 2006;8(3):R74. Epub 2006 Apr 21. Erratum in: Arthritis Res Ther. 2008;10(5):406.
Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, Brouwer E, Kallenberg CG, Bootsma H.
Arthritis Rheum. 2010 Apr;62(4):960-8.
Epratuzumab (humanised anti-CD22 antibody) in autoimmune diseases.
Steinfeld SD, Youinou P.
Expert Opin Biol Ther. 2006 Sep;6(9):943-9. Review.
Infliximab in patients with primary Sjögren's syndrome: a pilot study.
Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T.
Arthritis Rheum. 2001 Oct;44(10):2371-5.
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
Lindén O, Hindorf C, Cavallin-Ståhl E, Wegener WA, Goldenberg DM, Horne H, Ohlsson T, Stenberg L, Strand SE, Tennvall J.
Clin Cancer Res. 2005 Jul 15;11(14):5215-22.
Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study.
Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, Vissink A, Kallenberg CG, Bootsma H.
Arthritis Rheum. 2005 Sep;52(9):2740-50.
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
van Woerkom JM, Kruize AA, Geenen R, van Roon EN, Goldschmeding R, Verstappen SM, van Roon JA, Bijlsma JW.
Ann Rheum Dis. 2007 Aug;66(8):1026-32. Epub 2007 Jan 12.
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma.
Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Cesano A, Goldenberg DM.
J Clin Oncol. 2003 Aug 15;21(16):3051-9. Epub 2003 Jul 1.
Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).
Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, Roudaut A, Jamin C, Renaudineau Y, Roué IQ, Cochener B, Youinou P, Saraux A.
Arthritis Rheum. 2007 Mar 15;57(2):310-7.
Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study.
Fox RI, Dixon R, Guarrasi V, Krubel S.
Lupus. 1996 Jun;5 Suppl 1:S31-6.
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
Clin Cancer Res. 2004 Aug 15;10(16):5327-34.
Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J.
Arthritis Rheum. 2004 Apr;50(4):1270-6.
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA.
J Clin Oncol. 2006 Aug 20;24(24):3880-6. Epub 2006 Jul 24.
Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study.
Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, Richards A, Rauz S, Emery P.
Ann Rheum Dis. 2008 Nov;67(11):1541-4. Epub 2008 Feb 14.
[Expression of CD4+ CD25+ regulatory T cells in peripheral blood and salivary gland of patients with primary Sjögren's syndrome].
Li XM, Li XP, Qian L, Wang GS, Zhang H, Zhei ZM, Li Q, Chen K, Wang XQ, Wang YP.
Zhonghua Yi Xue Za Zhi. 2007 Apr 17;87(15):1034-6. Chinese.
A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
Khurshudian AV.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Jan;95(1):38-44.
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC; Children's Oncology Group Pilot Study.
J Clin Oncol. 2008 Aug 1;26(22):3756-62.
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.
Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T, Juan T, Talvenheimo J, Montestruque S, Sun J, Elliott G, Thomas J, Ferbas J, Kern B, Briddell R, Leonard JP, Cesano A.
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S.
Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjögren's syndrome.
Miyawaki S, Nishiyama S, Matoba K.
Intern Med. 1999 Dec;38(12):938-43.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on